Pearl, Inc. · Class II · Cleared Apr 11, 2025
| K-number | K242600 |
| Device name | Second Opinion Periapical Radiolucency Contours |
| Applicant | Pearl, Inc. |
| Product code | MYN |
| Device class | Class II |
| Decision date | Apr 11, 2025 |
| Decision | Substantially Equivalent |
| Regulation | 892.2070 |
Second Opinion PC is computer-aided detection (CADe) software that aids dentists in detecting periapical radiolucencies (bone loss around tooth roots) on periapical radiographs by displaying polygonal overlays highlighting suspected problem areas. It is designed for use by dental health professionals as a second reader to review radiographs of permanent teeth in patients 12 years or older, and is not intended to replace a dentist's clinical judgment.
Second Opinion PC uses neural network-based computer vision algorithms developed through supervised machine learning to detect periapical radiolucencies on digital intraoral radiographs processed on Windows operating systems. The key technological difference from the primary predicate device is that Second Opinion PC uses polygonal contours to mark detections, whereas the predicate Second Opinion uses bounding boxes, though both employ the same underlying machine learning approach and produce near-instantaneous results with graphical overlays.
Not stated in this summary.
Second Opinion PC is substantially equivalent because it maintains the same intended use (aiding dentists in detecting periapical radiolucencies as a second reader), employs the same core technology (neural network-based computer vision with machine learning), and demonstrated non-inferior clinical performance to the predicate device using a non-inferiority standalone study. The clinical study showed a wAFROC-FOM of 0.85 (95% CI 0.81-0.89) for the subject device versus 0.75-0.84 for the predicate, with the lower bound of the confidence interval exceeding the -0.05 non-inferiority margin, confirming equivalent or superior detection accuracy despite the change from bounding boxes to polygonal contours for visualization.
View the full FDA submission: accessdata.fda.gov